2020 | Business Wire
TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers.
2020 | Market Watch
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
2019 | Cision PR Newswire
BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.
2019 | PR Newswire
Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.
BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.
HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG
Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.
BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.
TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.
Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.
TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.
There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.
The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.
BNCT is a particularly promising technique for treating cancers of the head and neck region that are difficult or impossible to treat using other types of therapy. The procedure has already been tested in Japan, the United States and other locales.
TAE Life Sciences is the first to license TAE Technologies’ accelerator-based neutron beam technology for clinical investigation of Boron Neutron Capture Therapy (BNCT).
